Health and Fitness Health and Fitness
Mon, February 13, 2012
Sun, February 12, 2012
Fri, February 10, 2012
Thu, February 9, 2012
Wed, February 8, 2012
[ Wed, Feb 08th 2012 ] - Market Wire
Imaging3 Updates Website
Tue, February 7, 2012
Mon, February 6, 2012
Sun, February 5, 2012
[ Sun, Feb 05th 2012 ] - Market Wire
30 a.m. ET
Sat, February 4, 2012
Fri, February 3, 2012
Thu, February 2, 2012
Wed, February 1, 2012
Tue, January 31, 2012

Federman &;; Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against BioSante Pharmaceutical


//health-fitness.news-articles.net/content/2012/ .. -been-filed-against-biosante-pharmaceutical.html
Published in Health and Fitness on Tuesday, February 7th 2012 at 8:40 GMT by Market Wire   Print publication without navigation


February 07, 2012 11:37 ET

Federman & Sherwood Announces That a Securities Class Action Lawsuit Has Been Filed Against BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)

OKLAHOMA CITY, OK--(Marketwire - Feb 7, 2012) - On February 3, 2012, a class action lawsuit was filed in the United States District Court for the Northern District of Illinois against BioSante Pharmaceuticals, Inc. (NASDAQ: [ BPAX ]). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is February 12, 2010 through December 15, 2011.

Plaintiff seeks to recover damages on behalf of all BioSante Pharmaceuticals, Inc. shareholders who purchased common stock during the Class Period and are therefore a member of the Class as described above. You may move the Court no later than Friday, April 6, 2012 to serve as a lead plaintiff for the entire Class. However, in order to do so, you must meet certain legal requirements pursuant to the Private Securities Litigation Reform Act of 1995.

If you wish to discuss this action, obtain further information and participate in this or any other securities litigation, or should you have any questions or concerns regarding this notice or preservation of your rights, please contact:



Publication Contributing Sources